ARCUTIS BIOTHERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Increase (Decrease) in Prepaid Expense and Other Assets of $14.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $2.55M.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $11.73M, a 257.34% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $1.26M, a 1816.67% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $1.76M, a 58.60% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $2.01M, a 111.71% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $948.00K, a 89.00% decline from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $8.62M.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$3.47M, a 147.37% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $14.27M 10-Q · filed 2026-08-05 | $15.54M derived: sum of 3 quarters · filed 2026-08-05 | $17.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $11.73M 10-Q · filed 2026-05-06 | $12.99M derived: sum of 2 quarters · filed 2026-05-06 | $14.75M derived: sum of 3 quarters · filed 2026-05-06 | $10.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.02M derived: sum of 2 quarters · filed 2026-02-25 | -$1.27M derived: sum of 3 quarters · filed 2026-08-05 | $2.01M 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$2.54M derived: sum of 2 quarters · filed 2026-08-05 | $742.00K 10-Q · filed 2025-10-28 | $808.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$4.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.02M 10-Q · filed 2026-08-05 | -$952.00K derived: sum of 3 quarters · filed 2026-08-05 | $3.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.28M 10-Q · filed 2026-05-06 | $3.35M derived: sum of 2 quarters · filed 2026-05-06 | $7.60M derived: sum of 3 quarters · filed 2026-05-06 | $9.77M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.32M derived: sum of 2 quarters · filed 2026-02-25 | $6.49M derived: sum of 3 quarters · filed 2026-02-25 | $948.00K 10-K · filed 2026-02-25 |
| 2024-09-30 | $4.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $6.42M derived: sum of 2 quarters · filed 2025-10-28 | $882.00K 10-Q · filed 2025-10-28 | -$584.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$3.37M 10-Q · filed 2025-08-06 | -$4.83M derived: sum of 3 quarters · filed 2026-02-25 | $3.76M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$5.54M 10-Q · filed 2025-05-06 | -$7.00M derived: sum of 2 quarters · filed 2026-02-25 | $1.59M derived: sum of 3 quarters · filed 2026-02-25 | $668.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.13M derived: sum of 2 quarters · filed 2026-02-25 | $6.21M derived: sum of 3 quarters · filed 2026-02-25 | $8.62M 10-K · filed 2026-02-25 |
| 2023-09-30 | $8.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $7.67M derived: sum of 2 quarters · filed 2024-11-06 | $10.09M 10-Q · filed 2024-11-06 | $8.91M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$921.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.49M 10-Q · filed 2024-08-14 | $321.00K derived: sum of 3 quarters · filed 2025-02-25 | $81.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $2.42M 10-Q · filed 2024-05-14 | $1.24M derived: sum of 2 quarters · filed 2025-02-25 | $1.00M derived: sum of 3 quarters · filed 2025-02-25 | -$1.06M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$1.41M derived: sum of 2 quarters · filed 2025-02-25 | -$3.47M derived: sum of 3 quarters · filed 2025-02-25 | -$3.47M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$240.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$2.30M derived: sum of 2 quarters · filed 2023-11-03 | -$2.30M 10-Q · filed 2023-11-03 | -$1.08M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$2.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$2.06M 10-Q · filed 2023-08-08 | -$845.00K derived: sum of 3 quarters · filed 2024-02-27 | -$4.54M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $1.21M derived: sum of 2 quarters · filed 2024-02-27 | -$2.48M derived: sum of 3 quarters · filed 2024-02-27 | -$5.33M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$2.48M derived: sum of 2 quarters · filed 2024-02-27 | -$5.33M derived: sum of 3 quarters · filed 2024-02-27 | $7.33M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$3.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$6.55M derived: sum of 2 quarters · filed 2022-11-08 | $6.12M 10-Q · filed 2022-11-08 | $9.16M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$2.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $9.80M 10-Q · filed 2022-08-04 | $12.85M derived: sum of 3 quarters · filed 2023-02-28 | $12.59M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $12.66M 10-Q · filed 2022-05-05 | $15.71M derived: sum of 2 quarters · filed 2023-02-28 | $15.45M derived: sum of 3 quarters · filed 2023-02-28 | $14.98M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.78M derived: sum of 2 quarters · filed 2023-02-28 | $2.31M derived: sum of 3 quarters · filed 2023-02-28 | $3.41M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$260.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$728.00K derived: sum of 2 quarters · filed 2021-11-04 | $369.00K 10-Q · filed 2021-11-04 | $2.27M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | -$468.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $629.00K 10-Q · filed 2021-08-05 | $2.52M derived: sum of 3 quarters · filed 2022-02-22 | $2.36M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $1.10M 10-Q · filed 2021-05-06 | $2.99M derived: sum of 2 quarters · filed 2022-02-22 | $2.83M derived: sum of 3 quarters · filed 2022-02-22 | $4.09M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $1.73M derived: sum of 2 quarters · filed 2022-02-22 | $2.99M derived: sum of 3 quarters · filed 2022-02-22 | $3.30M 10-K · filed 2022-02-22 |
| 2019-09-30 | -$168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.09M derived: sum of 2 quarters · filed 2020-11-05 | $1.41M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $1.58M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $315.00K 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | -$243.00K 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |